Therapy News and Research

RSS

XOMA completes patient enrollment in XOMA 052 Phase 2a trial

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that patient enrollment was recently completed for the company's Phase 2a trial of XOMA 052 in patients with Type 2 diabetes.

29 Sep 2010

Report shows continuing progress in scaling up global HIV/AIDS interventions

The 2010 report on universal access to HIV prevention, care and treatment released today by WHO, UNAIDS, and UNICEF shows continuing progress in scaling up global HIV/AIDS interventions.

29 Sep 2010

Medical team uses LeadCare II blood-lead test to examine people exposed to lead poisoning in Nigeria

As part of the international response to the lead-poisoning crisis linked to small-scale gold-mining activities in this northwestern region of Nigeria, a medical crisis team is deploying Magellan's three-minute LeadCare II blood-lead test in the triage, assessment, and clinical follow-up of thousands of villagers who have been exposed to extremely high levels of lead in the soil and water.

29 Sep 2010

Advanced Dermatology and Ameriderm enters partnership with DermaGenoma for new acne screening test

As teens and twenty-somethings returned to school this month, many obsessed about their appearance, especially those with moderate to severe acne. A new screening test might save the day.

29 Sep 2010

African-American lung cancer patients with EGFR mutation respond better to erlotinib therapy

African-American patients with non-small cell lung cancer are just as likely to display an epidermal growth factor receptor (EGFR) mutation in tumors as Caucasians, which suggests they are as likely to benefit from targeted therapies such as erlotinib.

29 Sep 2010

Scientists develop NIA assay to determine drug's differential effects in tumor cells

A novel technology can make nanoscale protein measurements, which scientists can use in clinical trials to learn how drugs work.We are making progress toward the goal of understanding how drugs work in different individuals, said Alice C. Fan, M.D., instructor in the division of oncology at Stanford University School of Medicine.

29 Sep 2010

Canadians living with depression significantly underestimate others' perceptions about illness

A new national survey reveals a vast gap between how Canadians living with depression view their condition, compared to how it is viewed in reality by the general population, possibly preventing them from seeking the best treatment and care. Most Canadians with depression feel their illness is not perceived by the public as a medical condition or a serious illness (81 per cent) when in fact less than five per cent of the general population actually has that view. In fact, the majority of Canadians (72 per cent) recognize depression as both serious and treatable.

29 Sep 2010

Study finds PEM scanners equivalent to breast MRI in detecting cancerous lesions

In a prospective study published in the European Journal of Nuclear Medicine and Molecular Imaging, researchers at Boca Raton Regional Hospital (Boca Raton, FL) showed that Positron Emission Mammography (PEM) and breast MRI had comparably high ability to detect cancerous lesions.

29 Sep 2010

Synosia's SYN-118 HPPD inhibitor beneficial for Parkinson's patients: Study

Synosia Therapeutics today announced the first clinical study results showing that SYN-118 provides clinically meaningful benefits to Parkinson's patients, has a good safety profile and is well tolerated. Results from an open-label, proof-of-mechanism study of SYN-118 (CL02) were presented at the World Parkinson Congress in Glasgow, Scotland.

29 Sep 2010

Study finds broader statin use as a cost-effective way to prevent heart attack and stroke

A new analysis suggests that broader statin use among adult patients may be a cost-effective way to prevent heart attack and stroke. The Stanford University School of Medicine study also found that using a popular test - a screening for high sensitivity C-reactive protein, or CRP - to identify patients who may benefit from statin therapy would be cost-effective, but only under certain scenarios.

29 Sep 2010

New genetic screening program to reduce risk associated with Plavix

Beginning this month, all patients undergoing cardiac catheterization at Vanderbilt University Medical Center will be tested for a genetic variation that can affect their response to Plavix, the most commonly prescribed clot-preventing drug for heart patients and one of the most commonly prescribed drugs worldwide.

29 Sep 2010

Brain cells outside damaged area in stroke patients take on new roles

The world's largest study using neuroimaging of stroke patients struggling to regain ability to communicate finds that brain cells outside the damaged area can take on new roles.

29 Sep 2010

KINAXO, Daiichi Sankyo enter long-term partnership in cancer research

KINAXO Biotechnologies GmbH and Daiichi Sankyo Company Limited entered a long-term partnership in cancer research. Under the agreement, Daiichi Sankyo will employ KINAXO's technology platform to support the development of Daiichi Sankyo's targeted cancer drugs.

29 Sep 2010

Researchers unveil mechanism of candida infections

More than half of all people are hosts to Candida albicans in their bodies. This species might be located on their skin or mucous membranes or in the intestines frequently without causing any symptoms. However, it can be dangerous to patients whose immunological system has been weakened such as after organ transplants or chemotherapy with cancer. Then, this fungus penetrates into deeper layers of tissue and uses the blood system to spread throughout the body. In Germany alone, several thousand people die from systemic candida infections every year.

29 Sep 2010

Researchers identify biomarker to predict tivozanib drug resistance

Researchers believe there may be a way to predict, based on individual tumors, those patients that are more likely to respond to the investigational new drug tivozanib.

29 Sep 2010

Intrauterine devices for treatment of endometrial cancer

Intrauterine devices, originally developed as contraceptives, can also be used to treat and cure cancer of the endometrium according to new research published online in the cancer journal, Annals of Oncology today (Wednesday 29 September). The finding opens the way for young women with the disease, which affects the lining of the womb, to be treated without the need for a hysterectomy, thus preserving their fertility until they have had all the children they want.

29 Sep 2010

Early initiation of ART may prevent immune system damage in HIV patients: Study

HIV-infected individuals who begin antiretroviral therapy (ART) soon after acquiring the virus may have stronger immune responses to other pathogens than HIV-infected individuals who begin ART later, a new study from the National Institutes of Health has found. This finding suggests that early initiation of ART may prevent irreversible immune system damage and adds to the body of evidence showing significant health benefits from early ART.

29 Sep 2010

Combination therapy reduces radiographic evidence of joint destruction in rheumatoid arthritis: Study

A study conducted at Copenhagen University Hospital showed that treatment of rheumatoid arthritis (RA) with disease modifying antirheumatic drugs (DMARDs), glucocorticoids, biologic agents, or a combination of agents significantly reduced radiographic evidence of joint destruction, with a relative effect of 48%-72% as compared with placebo.

29 Sep 2010

Triple-negative breast cancer patients may have unique biomarker to receive targeted therapy: Research

Patients with triple negative breast cancer, one of the hardest subtypes to treat, may have a unique biomarker that would enable them to receive more targeted therapy, according to data presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.

29 Sep 2010

XenoPort to present XP21279 clinical trial data at World Parkinson Congress meeting

XenoPort, Inc. announced today that new data from its first clinical trial of XP21279, a Transported Prodrug of L-Dopa, in Parkinson's disease patients will be presented at the upcoming World Parkinson Congress meeting in Glasgow, Scotland.

29 Sep 2010

Therapy News and Research

XOMA completes patient enrollment in XOMA 052 Phase 2a trial

Report shows continuing progress in scaling up global HIV/AIDS interventions

Medical team uses LeadCare II blood-lead test to examine people exposed to lead poisoning in Nigeria

Advanced Dermatology and Ameriderm enters partnership with DermaGenoma for new acne screening test

African-American lung cancer patients with EGFR mutation respond better to erlotinib therapy

Scientists develop NIA assay to determine drug's differential effects in tumor cells

Canadians living with depression significantly underestimate others' perceptions about illness

Study finds PEM scanners equivalent to breast MRI in detecting cancerous lesions

Synosia's SYN-118 HPPD inhibitor beneficial for Parkinson's patients: Study

Study finds broader statin use as a cost-effective way to prevent heart attack and stroke

New genetic screening program to reduce risk associated with Plavix

Brain cells outside damaged area in stroke patients take on new roles

KINAXO, Daiichi Sankyo enter long-term partnership in cancer research

Researchers unveil mechanism of candida infections

Researchers identify biomarker to predict tivozanib drug resistance

Intrauterine devices for treatment of endometrial cancer

Early initiation of ART may prevent immune system damage in HIV patients: Study

Combination therapy reduces radiographic evidence of joint destruction in rheumatoid arthritis: Study

Triple-negative breast cancer patients may have unique biomarker to receive targeted therapy: Research

XenoPort to present XP21279 clinical trial data at World Parkinson Congress meeting

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News